Akari therapeutics announces $7.6 million private placement offering led by existing shareholders and insiders priced at the market under nasdaq rules

Boston and london, march 03, 2025 (globe newswire) -- akari therapeutics plc (nasdaq: aktx), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (adcs) for the treatment of cancer, today announced the successful pricing of a private placement financing round. this transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds.
NDAQ Ratings Summary
NDAQ Quant Ranking